Trailhead Biosystems Inc. products

We are currently developing a novel protocol that will use only small molecules to make human cortical interneurons of the forebrain from induced pluripotent stem cells (iPSCs). Our dopaminergic neurons can be used to accelerate the drug discovery process for treatments of neuropsychiatric disorders, schizophrenia, autism, and intellectual disabilities.

We have developed a novel three-stage protocol that uses only small molecules to make human dopaminergic neurons of the midbrain from induced pluripotent stem cells (iPSCs).

We have developed a novel three-stage protocol that uses only small molecules to make human oligodendrocyte progenitor cells (OPCs) of the forebrain from induced pluripotent stem cells (iPSCs).

We are currently developing a novel protocol that will use only small molecules to make human medium spiny neurons from human (non-embryo) induced pluripotent stem cells (iPSCs). We will use our medium spiny neurons as the foundation for a cell transplantation therapy for treating Huntington’s Disease, which we are developing.

We are developing these specialized human cells from human (non-embryo) induced pluripotent stem cells (iPSCs) using our proprietary HD-DOE™ research and development platform. We already have a nascent protocol for the generation of hypothalamic NPY-expressing cells. We believe that the delivery of specific subsets of hypothalamic cells from iPSC would be a gate-opener for the drug discovery industry.